About The structural genomics consortium (sgc)
The Structural Genomics Consortium (SGC) is a not-for-profit organization that has been making waves in the scientific community for its unique approach to research. The SGC's mission is to accelerate research by making all of its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in nine global pharmaceutical companies.
The SGC was founded in 2004 with a vision to create a new model for drug discovery that would be more efficient, cost-effective, and transparent than traditional approaches. The organization's focus is on structural genomics - the study of protein structures - which plays a critical role in understanding disease mechanisms and developing new drugs.
One of the key features that sets the SGC apart from other organizations is its commitment to open science. All of its research output, including data, reagents, and knowledge, are made freely available to researchers worldwide through public databases such as PDB (Protein Data Bank) and ChEMBL (Chemical Biology Database). This approach has been highly successful; since its inception, the SGC has published over 1,000 structures in PDB alone.
Another important aspect of the SGC's work is collaboration. The organization brings together scientists from different disciplines and institutions around the world to work on common goals. This collaborative network includes over 3,000 researchers from more than 350 universities across six continents. By working together on shared projects such as target validation or drug discovery programs, these scientists can achieve results faster than they could working alone.
The SGC also collaborates with industry partners who share their commitment to open science. Nine global pharmaceutical companies have joined forces with the consortium so far: AbbVie Inc., Bayer AG., Boehringer Ingelheim International GmbH., Canada Foundation for Innovation (CFI), Eshelman Institute for Innovation at UNC-Chapel Hill School of Pharmacy, Genentech Inc., GlaxoSmithKline plc., Janssen Pharmaceutica NV, and Takeda Pharmaceutical Company Limited. These partnerships allow the SGC to leverage industry expertise and resources while maintaining its commitment to open science.
The SGC's research focuses on a range of diseases, including cancer, diabetes, neurodegenerative disorders, and infectious diseases. By studying the structures of proteins involved in these diseases, the organization aims to identify new drug targets and develop more effective treatments. Some of their recent successes include identifying a potential new target for pancreatic cancer treatment and discovering a compound that could be used to treat malaria.
In addition to its research activities, the SGC also provides training opportunities for young scientists through its graduate student program and postdoctoral fellowships. These programs offer hands-on experience in structural genomics research as well as opportunities for collaboration with other scientists around the world.
Overall, the Structural Genomics Consortium is an innovative organization that is changing the way we approach drug discovery. Its commitment to open science and collaboration has already yielded impressive results in terms of scientific output and impact on human health. As it continues to grow its network of collaborators around the world, we can expect even more exciting discoveries from this groundbreaking organization in years to come.
thesgc.org
